Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 177

The DOI matches its Crossref record.

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

Spigel, David R., Schrock, Alexa Betzig, Fabrizio, David, Frampton, Garrett Michael, Sun, James, He, Jie, Gowen, Kyle, Johnson, Melissa Lynne, Bauer, Todd Michael, Kalemkerian, Gregory Peter, Raez, Luis E., Ou, Sai-Hong Ignatius, Ross, Jeffrey S., Stephens, Philip J., Miller, Vincent A., Ali, Siraj Mahamed · 2016 · Journal of Clinical Oncology

Abstract

9017 Background: Immune checkpoint inhibitor (ICPI) therapies, including nivolumab and pembrolizumab, have been FDA-approved in squamous and non-squamous non-small cell (LC). Current IHC based diagnostics are challenged by assay and slide scoring issues, and more robust and comprehensive biomarkers of ICPI efficacy are needed. Methods: Comprehensive genomic profiling (CGP) was performed on FFPE specimens during the course of clinical care. TMB (mutations/Mb) was assessed as the number of somatic, coding, base substitution and indel alterations per Mb of genome. The top quartile of LC was classified as TMB high. Microsatellite instable (MSI-H) or stable (MSS) status was determined using a proprietary computational algorithm. Results: TMB was similar across all LC histologies, but elevated compared to an average TMB of 7.3 for all 60,000+ samples in the database. TMB was consistently low in LC harboring known drivers, with the exception of BRAF or KRAS mutant tumors. (See Table.) 22/5,895 LC cases (0.4%) assessed were MSI-H and 5,849 (99%) were MSS. 21/22 MSI-H cases had high TMB, and represented 9 Adeno, 7 NSCLC NOS, 5 SCC, and 1 SCLC. Alterations in BRCA1, BRCA2, and POLE were significantly enriched in LC with high TMB. 85 (0.7%) of 11,662 LC had PD-L1amplification. Responses to PD-1/PD-L1 targeted therapies and dependence on TMB will be presented. Conclusions: TMB was consistent across LC histologies and was significantly reduced in most LC with confirmed druggable oncogenic drivers, but not in KRAS or BRAF mutated cases. MSI-H status strongly correlated with high TMB. CGP of LC to simultaneously determine TMB, MSI status, PD-L1 amplification, and the presence of driver alterations may provide clinically useful predictors of response to ICPI and other targeted therapies. Adeno (n=7,925) SCC (n=1,324) NSCLC NOS (n=1,773) SCLC (n=640) EGFR mutation (n=1,775) ALK or ROS1 fusion (n=489) METex14 alteration (n=286) BRAF mutation (n=493) KRAS mutation (n=3,155) Mean 9.1 11.3 11.0 10.3 4.5 3.1 6.2 9.7 10.3 TMB > 10 (%) 2350 (30) 541 (41) 711 (40) 269 (42) 129 (7) 17 (3) 27 (9) 153 (31) 1,238 (39) TMB > 20 (%) 760 (10) 113 (9) 233 (13) 42 (7) 21 (1) 4 (1) 4 (1) 51 (10) 298 (9) Wilcoxon signed-rank test vs KRAS P<0.001 P<0.001 P<0.001 P<0.001

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.34.15_suppl.9017

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 177

Metadata

Authors
Spigel, D. R., Schrock, A. B., Fabrizio, D., Frampton, G. M., Sun, J., He, J., Gowen, K., Johnson, M. L., Bauer, T. M., Kalemkerian, G. P., Raez, L. E., Ou, S.-H. I., Ross, J. S., Stephens, P. J., Miller, V. A., & Ali, S. M.
Venue
Journal of Clinical Oncology
Published
2016-05-20
Volume
34
Issue
15_suppl
Pages
9017-9017
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2683488101
Cited by
177
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.9017
The paper
Spigel, D. R., Schrock, A. B., Fabrizio, D., Frampton, G. M., Sun, J., He, J., Gowen, K., Johnson, M. L., Bauer, T. M., Kalemkerian, G. P., Raez, L. E., Ou, S.-H. I., Ross, J. S., Stephens, P. J., Miller, V. A., & Ali, S. M. (2016). Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.9017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.